{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:10:18Z","timestamp":1761127818246,"version":"3.33.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1136\/ard.61.9.822","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T19:54:10Z","timestamp":1033502050000},"page":"822-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis"],"prefix":"10.1016","volume":"61","author":[{"given":"T I","family":"Temekonidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A N","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Alamanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D V","family":"Bougias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P V","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A A","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.61.9.822_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81109-5","article-title":"Rheumatoid arthritis","volume":"85","author":"Feldmann","year":"1996","journal-title":"Cell"},{"key":"10.1136\/ard.61.9.822_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.61.9.822_bib3","first-page":"28","article-title":"Cytokines in rheumatoid arthritis","volume":"43","author":"Koch","year":"1995","journal-title":"J Invest Med"},{"key":"10.1136\/ard.61.9.822_bib4","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The tumor necrosis factor ligand and receptor family","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.61.9.822_bib5","first-page":"994","article-title":"Termination of slow acting anti\u2013rheumatic therapy in rheumatoid arthritis: a 14\u2013year prospective evaluation of 1047 consecutive starts","volume":"17","author":"Wolfe","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.9.822_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate in severe rheumatoid arthritis","volume":"333","author":"Tugwell","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.61.9.822_bib7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hychoxychloroquine or a combination of all three medications","volume":"334","author":"O'Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.61.9.822_bib8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti\u2013tumor necrosis factor a monoclonal antibody combined with low\u2013dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.9.822_bib9","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (climatic anti\u2013tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase II trial. ATTRACT Study group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.61.9.822_bib10","first-page":"261","article-title":"Disease modifying anti\u2013rheumatic drugs in early rheumatoid arthritis: a long\u2013term observational study","volume":"29","author":"Papadopoulos","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.9.822_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.9.822_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.9.822_bib13","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","article-title":"Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?","volume":"41","author":"Felson","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.9.822_bib14","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/1529-0131(199810)41:10<1806::AID-ART12>3.0.CO;2-9","article-title":"Therapeutic actions of cyclosporine and anti\u2013tumor necrosis factor \u03b1 in collagen\u2013induced arthritis and the effect of combination therapy","volume":"41","author":"Williams","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.9.822_bib15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724092434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724092434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.61.9.822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:58:57Z","timestamp":1737349137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724092434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S0003496724092434"],"URL":"https:\/\/doi.org\/10.1136\/ard.61.9.822","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2002,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.61.9.822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Copyright 2002 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}